English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Sir, We read with interest the use of eculizumab as a protection against complement-mediated damage in a murine model of the Miller Fisher syndrome (MFS). This monoclonal antibody not only resulted in protection against functional and morphological terminal motor neuropathy, but effectively prohibited respiratory muscle paralysis (Halstead et al. , 2008). These important findings have provided the basis for human trials in MFS, its related disorders of Bickerstaff's brainstem encephalitis (BBE) and Guillain-Barre syndrome (GBS), as well as neuropathies in which antibody-mediated complement activation may be pathophysiologically important (Compston, 2008; Lehmann and Hartung, 2008).MFS, BBE and GBS are now widely regarded as part of a continuous spectrum of disorders whereby anti-GQ1b IgG antibody plays a vital part in the pathogenesis, although other antibody involvement may be contributory (Odaka et al. , 2001; Lo, 2007). Evidence of …

Immunotherapy for anti-GQ1b IgG antibody-mediated disorders: role of electrophysiology in human trials